FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W285405205> ?p ?o ?g. }

• W285405205 startingPage "21" @default.
• W285405205 abstract "Equipped with the knowledge that the Human Genome Project yielded, (1) biomedical researchers and clinicians are looking to enhance human health. Research to understand both the interaction between genes and pharmaceutical drugs and the interaction between genes and nutrients is quickly helping to develop new genomic applications. Is Canadian law well prepared to handle these advances? An examination of federal law addresses pharmacogenomics (2) and (3) may help provide an answer. This comparison is particularly compelling in light of growing anticipation that a new era of personalized medicine has dawned. (4) Indeed, both pharmacogenomics and aim to personalize (5) medicine and nutrition, and ultimately health, by tailoring drugs or foods to individual genotypes. (6) Specifically, through pharmacogenomics, it will become possible to individualize therapies, (7) adapting a patient's treatment by selecting optimal drugs, adjusting dosage, or managing potential adverse effects. (8) Similarly, personalized nutrition will entail decisions about nutrition and overall health based on an individual's knowledge of nutrition and of their genetic make-up, informed either by means of genetic testing or indirectly through family history or personal experience. (9) Moreover, as both pharmacogenomics and explore how whether naturally occurring or manufactured, alter and regulate biological processes and individual genetic variation influences the responses to those chemicals, (10) some researchers have suggested that nutrigenomics and pharmacogenomics may best be viewed not only as a continuum but also as inseparable in clinical applications. Indeed, the emerging knowledge of nutrient-gene interactions shows that certain chemicals in food directly alter the same molecular pathways targeted by drugs, or alter interacting pathways that may influence drug efficacy. (11) In 2000, the pharmaceutical company Novartis and the food manufacturer Quaker Oats formed Altus Food to develop functional foods and beverages offering scientifically proven health benefits beyond basic nutrition. (12) Although the joint venture did not survive a subsequent merger between Pepsi-Co and Quaker, (13) it remains an indication of potential genomic-based corporate convergences. This article does not pretend to assess fully whether Canadian law is compatible with or supportive of genomic advances. Rather, it points to many legal considerations that would need careful examination to derive a definitive answer. This overview begins with a brief discussion of the research and development challenges that confront both the pharmaceutical and food sectors, and the leverage genomic technologies may bring. It also reviews the regulation of clinical trials with a focus on relevant genomic aspects. Finally, it points to potential liability risks that manufacturers or health care professionals may encounter once genomic products and services become more widely available. Food and Drug Research & Development During the research and development phases, new drugs and new food products face significant challenges, even though they go through markedly different channels: one commentator noted that the pharmaceutical industry operates in the world of rational drug design and clinical trials where physicians ultimately intervene in decisions regarding patients and medication, whereas the food industry operates in the world of taste and convenience where trials are limited and products are promoted directly to consumers. (14) However, using genomics, it is possible the two worlds will move closer together, a trend already started with the scientifically based health claims made in relation to certain foods. The challenges of pharmaceutical companies are well known: in the US, the number of new drug applications for major drug products or of biological license applications for new molecular entities submitted to the Food and Drug Administration (FDA) has steadily decreased over the past 15-20 years. …" @default.
• W285405205 created "2016-06-24" @default.
• W285405205 creator A5080450490 @default.
• W285405205 date "2008-06-22" @default.
• W285405205 modified "2023-09-23" @default.
• W285405205 title "Canadian Legal Oversight of Pharmacogenomics and Nutrigenomics" @default.
• W285405205 cites W1137769402 @default.
• W285405205 cites W1515820300 @default.
• W285405205 cites W1544215382 @default.
• W285405205 cites W1955507806 @default.
• W285405205 cites W1963885493 @default.
• W285405205 cites W1971784646 @default.
• W285405205 cites W1991296676 @default.
• W285405205 cites W1998720401 @default.
• W285405205 cites W2007745104 @default.
• W285405205 cites W2017016814 @default.
• W285405205 cites W2022706240 @default.
• W285405205 cites W2034898905 @default.
• W285405205 cites W207711372 @default.
• W285405205 cites W2086708189 @default.
• W285405205 cites W2098598367 @default.
• W285405205 cites W2115598136 @default.
• W285405205 cites W2130987666 @default.
• W285405205 cites W2154617836 @default.
• W285405205 cites W215866210 @default.
• W285405205 cites W2164236577 @default.
• W285405205 cites W2261119910 @default.
• W285405205 cites W2410308529 @default.
• W285405205 cites W2486448731 @default.
• W285405205 cites W2790907348 @default.
• W285405205 hasPublicationYear "2008" @default.
• W285405205 type Work @default.
• W285405205 sameAs 285405205 @default.
• W285405205 citedByCount "0" @default.
• W285405205 crossrefType "journal-article" @default.
• W285405205 hasAuthorship W285405205A5080450490 @default.
• W285405205 hasConcept C104317684 @default.
• W285405205 hasConcept C142724271 @default.
• W285405205 hasConcept C150903083 @default.
• W285405205 hasConcept C154945302 @default.
• W285405205 hasConcept C163763905 @default.
• W285405205 hasConcept C170734499 @default.
• W285405205 hasConcept C176777502 @default.
• W285405205 hasConcept C32220436 @default.
• W285405205 hasConcept C41008148 @default.
• W285405205 hasConcept C54355233 @default.
• W285405205 hasConcept C60644358 @default.
• W285405205 hasConcept C71924100 @default.
• W285405205 hasConcept C86803240 @default.
• W285405205 hasConcept C97633540 @default.
• W285405205 hasConcept C98274493 @default.
• W285405205 hasConceptScore W285405205C104317684 @default.
• W285405205 hasConceptScore W285405205C142724271 @default.
• W285405205 hasConceptScore W285405205C150903083 @default.
• W285405205 hasConceptScore W285405205C154945302 @default.
• W285405205 hasConceptScore W285405205C163763905 @default.
• W285405205 hasConceptScore W285405205C170734499 @default.
• W285405205 hasConceptScore W285405205C176777502 @default.
• W285405205 hasConceptScore W285405205C32220436 @default.
• W285405205 hasConceptScore W285405205C41008148 @default.
• W285405205 hasConceptScore W285405205C54355233 @default.
• W285405205 hasConceptScore W285405205C60644358 @default.
• W285405205 hasConceptScore W285405205C71924100 @default.
• W285405205 hasConceptScore W285405205C86803240 @default.
• W285405205 hasConceptScore W285405205C97633540 @default.
• W285405205 hasConceptScore W285405205C98274493 @default.
• W285405205 hasIssue "3" @default.
• W285405205 hasLocation W2854052051 @default.
• W285405205 hasOpenAccess W285405205 @default.
• W285405205 hasPrimaryLocation W2854052051 @default.
• W285405205 hasRelatedWork W1539029631 @default.
• W285405205 hasRelatedWork W1979957974 @default.
• W285405205 hasRelatedWork W2011380042 @default.
• W285405205 hasRelatedWork W2013277740 @default.
• W285405205 hasRelatedWork W2030214993 @default.
• W285405205 hasRelatedWork W2081312590 @default.
• W285405205 hasRelatedWork W2092092977 @default.
• W285405205 hasRelatedWork W2098031586 @default.
• W285405205 hasRelatedWork W2184459226 @default.
• W285405205 hasRelatedWork W238702345 @default.
• W285405205 hasRelatedWork W2408632352 @default.
• W285405205 hasRelatedWork W2410240015 @default.
• W285405205 hasRelatedWork W2417472551 @default.
• W285405205 hasRelatedWork W2461609121 @default.
• W285405205 hasRelatedWork W249548385 @default.
• W285405205 hasRelatedWork W2949257517 @default.
• W285405205 hasRelatedWork W3115531266 @default.
• W285405205 hasRelatedWork W3122207308 @default.
• W285405205 hasRelatedWork W3122982304 @default.
• W285405205 hasRelatedWork W3193300643 @default.
• W285405205 hasVolume "16" @default.
• W285405205 isParatext "false" @default.
• W285405205 isRetracted "false" @default.
• W285405205 magId "285405205" @default.
• W285405205 workType "article" @default.